Today: 1 July 2026
Browse Category

Pharmaceutical Industry 18 April 2026 - 29 June 2026

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

AbbVie stock run lifts pricing on $10.9 billion Apogee deal to six times cost

U.S. cash equities didn’t trade Sunday, so AbbVie’s most recent close is Friday at $253.35. That’s a 4.2% gain for the day and up 17.0% since June 18, which was the last session ahead of the Juneteenth break and before AbbVie’s deal week kicked off. The scale stands out. With 1.77 billion shares out, going from $216.49 to $253.35 pushed market value up around $65 billion. AbbVie said it will buy Apogee for $10.9 billion in cash. Apogee closed Friday at $132.55, about 1.9% under the $135.11 cash offer.
29 June 2026
···
Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines stock ends week back above IPO price as volume jumps

Generate Biomedicines, Inc. ended a short U.S. trading week back over its IPO price, a sharper test for investors than the 0.3% Friday close suggests. The shares closed at $16.47, touched a 52-week high of $17.42 this week and traded 4.10 million shares Friday against average volume of 934,290. From the June 18 close of $14.49, the last close before the Juneteenth market holiday, through Friday’s close, GENB rose 13.7%. It closed above $16 on Wednesday, Thursday and Friday, after closing at $15.89 on Monday and $15.43 on Tuesday.
27 June 2026
··
SELLAS Life Sciences (NASDAQ:SLS) rises as short interest builds, company files change-control ahead of AML update

SELLAS Life Sciences (NASDAQ:SLS) rises as short interest builds, company files change-control ahead of AML update

SELLAS Life Sciences Group climbed 6.3% to $11.19 in early trade Friday, reaching as high as $11.29. The stock outpaced the broader biotech sector, with State Street’s SPDR S&P Biotech ETF gaining 1.8%. SLS volume jumped Thursday, trading 15.11 million shares on June 25, close to double its 65-day average of 7.57 million. The stock closed at $10.53 after reaching $11.06, according to FactSet data from the Wall Street Journal.
26 June 2026
··
Centessa (NASDAQ:CNTA) final price leaves Lilly (NYSE:LLY) CVR at about 28% of max

Centessa (NASDAQ:CNTA) final price leaves Lilly (NYSE:LLY) CVR at about 28% of max

Centessa Pharmaceuticals plc shares were not trading live on Friday, but this wasn’t due to a holiday. Trading in New York was open at 10:04 a.m. EDT, with the Nasdaq’s regular session running 9:30 a.m. to 4:00 p.m. ET. There’s no market closure for June 26 on the 2026 holiday list. Centessa shares stopped trading after its buyout by Eli Lilly and Company closed. The Nasdaq Composite started off down 1.0% at 25,105.414 on Friday, but CNTA isn't part of the usual public action anymore.
26 June 2026
···
Viking Therapeutics Stock Jumps as Obesity Drug Catalyst Nears

Viking Therapeutics Stock Jumps as Obesity Drug Catalyst Nears

Viking Therapeutics shares rose sharply in Tuesday afternoon trading, climbing 6.0% to $34.30 as investors moved back into the clinical-stage biotech ahead of expected updates on its lead obesity-drug program. The Nasdaq-listed stock traded as high as $35.90 after opening at $31.76, with volume above 5.1 million shares. The move mattered because Viking is no longer just an early obesity-drug story. Its lead candidate, VK2735, is in Phase 3 testing — late-stage trials generally used to support a regulatory filing — and the company has told investors it expects data from a maintenance-dosing study in the third quarter of 2026.
23 June 2026
··
Nexentis Soars 156% on AI Drug Discovery Plans, Shares Fall After the Bell

Nexentis Soars 156% on AI Drug Discovery Plans, Shares Fall After the Bell

Nexentis Technologies Inc. shares soared more than 100% on Monday after a new AI drug-discovery update hit the tape. The small Nasdaq-listed name drew heavy trading interest for most of the session, though the stock pulled back some in after-hours trade. Shares ended the regular session at $13.00, up 155.91%. The stock traded from $11.00 to $23.80. Trading volume came in at 60.3 million shares, far above the 65-day average of 198,960. A delayed MarketWatch quote showed the stock falling 26.15% after hours to $9.60.
23 June 2026
···
Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover

Apogee Therapeutics (NASDAQ:APGE) stock jumps on AbbVie’s $10.9 billion cash takeover

Apogee Therapeutics shares surged on Monday after AbbVie agreed to acquire the biotech company for $10.9 billion in cash, giving the U.S. drugmaker control of a long-acting immunology drug candidate aimed at eczema and asthma. Apogee was recently trading at $132.69, up about 47%, against AbbVie’s $135.11-a-share offer. The move matters now because Apogee’s lead drug, zumilokibart, is nearing late-stage testing just as large pharmaceutical companies are paying up for pipeline assets that can replace aging blockbusters. AbbVie said Apogee’s portfolio would deepen its immunology business and accelerate its move into respiratory disease.
22 June 2026
···
Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics Gains as FDA Timeline for Lytenava Comes Up

Outlook Therapeutics shares surged Wednesday as the stock once again drew regulatory-timer trades after the company filed its newest FDA application for ONS-5010/LYTENAVA, its candidate for wet age-related macular degeneration. The stock was last quoted near $0.89, up about 26% from Tuesday's close, with shares trading between $0.6853 and $0.8999 and volume near 21.9 million shares. Investors are focused on timing. Outlook said June 1 it resubmitted its Biologics License Application, or BLA, for ONS-5010/LYTENAVA to the FDA. The drug targets neovascular age-related macular degeneration, or wet AMD, which affects central vision.
10 June 2026
··
Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax Shares Drop After Trial Win and Cancer Cases Raise Concerns

Abivax shares dropped hard Tuesday, despite positive late-stage trial results for its obefazimod drug. Investors focused on reported cancer and dysplasia cases in patients on the higher dose. The stock traded at 63.10 euros on Euronext Paris, well below Monday’s closing price of 111.80 euros, after touching 62.80 euros earlier. Over in the U.S., its Nasdaq ADRs were last at $72.86, down some 44% late in the session. Abivax had turned into one of Europe’s biggest biotech bets, as most of its price depended on obefazimod’s prospects as an oral ulcerative colitis drug. Reuters said its shares led the drop on Europe’s STOXX 600 in Paris this morning. The stock had surged over 16 times last year.
2 June 2026
····
Why AIM ImmunoTech Stock More Than Doubled Today After a Pancreatic Cancer Trial Surprise

Why AIM ImmunoTech Stock More Than Doubled Today After a Pancreatic Cancer Trial Surprise

AIM ImmunoTech Inc. shares more than doubled on Monday after the drug developer said the final planned subject in its Phase 2 DURIPANC pancreatic-cancer trial had met enrollment criteria, putting the study ahead of its earlier July target. The stock was recently at 92.79 cents, up 52.01 cents on the session, on volume of more than 312 million shares. Its intraday range ran from 42.33 cents to $1.215, a wide move even by small biotech standards.
1 June 2026
··
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio shares were active before the Nasdaq bell on Monday after the company said five U.S. patents will protect its Anktiva-plus-BCG bladder cancer treatment into at least 2035. This statement followed Friday’s announcement of an exclusive U.S. supply deal with Japan BCG Laboratory. The stock last traded at $7.97, unchanged from Friday’s close, when it slipped 2.2% on volume of 11.3 million shares. Nasdaq regular trading hadn’t started yet. The exchange’s posted hours run 9:30 a.m. to 4 p.m. Eastern, with pre-market trading open 4 a.m. to 9:30 a.m. Memorial Day, May 25, is the next scheduled U.S. market holiday in 2026.
18 May 2026
··
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio Inc. shares will react Monday to news of a fresh bladder-cancer supply agreement. The company said Saturday it now has exclusive U.S. rights to develop, import and sell the Tokyo-172 BCG strain from Japan BCG Laboratory. ImmunityBio’s main drug Anktiva is already approved to be used with Bacillus Calmette-Guerin, or BCG, for some non-muscle invasive bladder cancers, meaning cancers that haven’t spread into the bladder wall. BCG was first developed as a tuberculosis vaccine but is also given in the bladder to kickstart the immune system against tumors. ImmunityBio said its new Japan deal could bring a second possible U.S. supply of BCG.
17 May 2026
··
Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Biogen Closes Apellis Deal; APLS Leaves Nasdaq As $5.6 Billion Rare-Disease Bet Begins

Cambridge, Massachusetts, May 15, 2026, 10:08 EDT Biogen said Thursday it has wrapped up its purchase of Apellis Pharmaceuticals, bringing Apellis under its wing as a fully owned subsidiary. The deal takes Apellis off the Nasdaq as an independent biotech, and hands Biogen ownership of its two approved drugs, which join Biogen’s rare-disease division.
15 May 2026
···
Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

Avalo Therapeutics Stock Jumps As $375 Million Raise Follows Phase 2 HS Trial Win

WAYNE, Pa., May 6, 2026, 12:04 Late Tuesday, Avalo Therapeutics Inc. locked in a $375 million public offering—just hours after rolling out upbeat Phase 2 results for abdakibart. Riding the surge of interest tied to its hidradenitis suppurativa program, the company aims to fund its looming Phase 3 plans. Avalo is set to offer 19.73 million shares at $17.75 apiece, along with pre-funded warrants for another 1.4 million shares at $17.749 each. Closing is slated for May 7, pending standard closing conditions.
6 May 2026
··
Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Just Got a First-of-Its-Kind Breast Cancer Approval. The Bigger Test Comes This Week

Pfizer Inc. and Arvinas scored FDA approval for Veppanu, a breast cancer pill, adding a fresh weapon to Pfizer’s oncology lineup. With this nod, Pfizer gains ground in its push to prove it can replace waning sales from legacy products after the COVID boom. Pfizer’s upcoming first-quarter earnings, set for Tuesday, put a fresh spotlight on growth prospects, looming patent cliffs, and the payoff from its latest drug pipeline moves. Management fields analyst questions during a call slated for 10 a.m. EDT on May 5.
3 May 2026
··
Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge

Summit Therapeutics Stock Plunges 23%: The Ivonescimab Update Shaking Its Keytruda Challenge

Summit Therapeutics Inc. dropped roughly 23% Friday afternoon after the HARMONi-3 update disappointed—ivonescimab, the biotech’s high-profile lung cancer hopeful, didn’t deliver the early upside investors were hunting for. Shares last traded at $16.60. Merck & Co., running Keytruda as the trial comparator, moved up 3%. The selloff packs a punch because ivonescimab sits at the heart of Summit’s pipeline. Known as SMT112 in Summit’s covered territories, this bispecific antibody targets both PD-1, an immune checkpoint, and VEGF, the signal for tumor blood vessel growth, within a single drug. Summit licenses the therapy from Akeso, holding rights across the Americas, Europe, Japan, and a range of other markets outside Akeso’s retained regions.
1 May 2026
··
Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics jumped to secure $500 million through stock and pre-funded warrants Monday, following a spike in its shares after interim results from its investigational psoriasis treatment. The surge also sparked new comparisons to big-name drugs from AbbVie and UCB. The timing works in Oruka’s favor. Investors, on the hunt for fresh players in the psoriasis landscape, took notice as the latest data landed. In this space, dosing ease and strong skin-clearance numbers influence prescribing choices. ORKA-001, Oruka’s candidate, is designed as a longer-acting injectable—potentially needed just once or twice a year, according to the company.
27 April 2026
···
Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics Inc. is heading into a heavy clinical-data stretch with fresh Wall Street backing, after Stifel analyst Paul Matteis initiated coverage of the Nasdaq-listed company with a Buy rating and a $30 price target. The focus is DT120 ODT, an orally disintegrating tablet form of lysergide D-tartrate, better known as LSD, now in late-stage trials for anxiety and depression. The timing matters. Definium has scheduled an investor and analyst day in New York for April 22, where the company says management and outside clinical experts will discuss DT120, expected 2026 top-line data and the drug’s potential market opportunity. Top-line data means the first headline results from a clinical trial, before fuller analysis follows.
18 April 2026
··
1 2 3 … 9

Stock Market Today

  • Sensex, Nifty Edge Up as Auto Leads, Rainfall Deficit Caps Gains
    July 1, 2026, 1:22 AM EDT. The BSE Sensex added 181.28 points to 76,659.95 and NSE Nifty50 rose 49.90 points to 23,915.65, lifted by auto stocks but held back by a 40% rainfall deficit in June and a lack of progress in US-Iran talks. Sector action was mixed - Nifty Media up 1.63%, Nifty Metal down 0.72%. Among major Sensex players, Mahindra & Mahindra gained 2.05%, Titan added 1.44%. Bajaj Finserv lost 2.13%. Crude hovered near $73 a barrel, helping inflation views, but market tone turned cautious on geopolitics. Analysts pointed to monsoon deficiencies as an increasing drag on the farm sector and economy.
Go toTop